PREZISTA®: now one tablet per day in combination with other antiretrovirals for:

- Treatment-naive patients regardless of viral load
- Treatment experienced patients with no DRV RAMs
- HIV-1 <100,000 copies/ml and CD4 cell count >100 cells x 10^3/l!

**PRESCRIBING INFORMATION**

**PREZISTA® 100mg/ml oral suspension and 75 mg, 150 mg, 400 mg, 600 mg and 800 mg film-coated tablets**

**Active ingredients:** Darunavir (as ethanolate). Oral suspension = 100mg/ml. Film-coated tablets = 75 mg, 150 mg, 400 mg, 600 mg or 800 mg. See **Summary of Product Characteristics (SmPC)** before prescribing.

**INDICATIONS:** PREZISTA, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV) infection.

**PREZISTA** Oral suspension, 75 mg, 150 mg and 600 mg tablets may be used to provide suitable dose regimens. For the treatment of HIV-1 infection in antiretroviral treatment (ART) experienced adult patients (including highly pre-treated). For the treatment of HIV-1 infection in ART-experienced paediatric patients from the age of 2 years and at least 15 kg body weight. PREZISTA 200 mg and 800 mg tablets may be used to provide suitable dose regimens. For the treatment of HIV-1 infection in antiretroviral therapy (ART) naive adults. For the treatment of HIV-1 infection in ART-experienced adults with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA <100,000 copies/ml and CD4 cell count <300 cells x 10^3/l. Genotypic or phenotypic testing (when available) and treatment history should guide the use of PREZISTA.

**DOSEAGE AND ADMINISTRATION:** Therapy should be initiated by health care provider experienced in management of HIV. PREZISTA must be taken with food. ART-naive adults: PREZISTA 800 mg once daily with ritonavir 100 mg once daily. ART naive children: Not recommended for use. ART-experienced adults with no DRV-RAMs: PREZISTA 800 mg once daily with ritonavir 100 mg once daily. All other ART-experienced adults: 600 mg, 800 mg, 1,000 mg and 1,200 mg ritonavir twice daily. ART-experienced paediatric patients: >15 kg and ≤30 kg: 375 mg (3.8ml) PREZISTA/50 mg (0.6ml) ritonavir twice daily. >30 kg and ≤45 kg: 450 mg (4.6ml) PREZISTA/60 mg (0.8ml) ritonavir twice daily. >45 kg: 600 mg (6ml) PREZISTA/100 mg (1.2ml) ritonavir twice daily. PREZISTA oral suspension can be used in patients unable to swallow PREZISTA tablets. Children < 3 years of age or ≤15 kg body weight: Not recommended. Elderly: Limited information available. Use with caution.

**Hepatic impairment:** Use with caution in patients with mild or moderate hepatic impairment and contraindicated in patients with severe hepatic impairment. Renal impairment: No dose adjustment required. **CONTRAINDICATIONS:** Hypersensitivity to active substance or any excipients. Severe hepatic impairment. Combination of rifampin/ritonavir or lopinavir/ritonavir with PREZISTA. Preparations containing St John’s wort. Active substances that are CYP3A4 inhibitors. **Known sulphonamide allergy:** Contains a sulphonamide moiety; caution advised.

**Pharmacokinetics:** Darunavir has been reported. Patients with pre-existing liver dysfunction including chronic active hepatitis B or C have increased risk of liver function abnormalities including severe/fatal hepatic adverse events and should be monitored. Possible increased risk of hepatic adverse events and should be monitored. Short-term therapy (≤8 weeks) is recommended. Long-term therapy (>8 weeks) is not recommended.

**INTERACTIONS:** Darunavir is a potent CYP3A4 inhibitor. Clinical pharmacokinetic interaction studies between darunavir/ritonavir and HIV-1 protease inhibitors have been performed. Darunavir is a moderate inhibitor of CYP1A2 and CYP3A4. Darunavir is a potent inhibitor of CYP2C9 and CYP2C19. Darunavir is a moderate inhibitor of CYP2D6, CYP2E1 and CYP2J2. Darunavir is a weak inhibitor of CYP2C8, CYP2C18, CYP2C19 and CYP2D6. Darunavir does not inhibit CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2F2, CYP2G1, CYP3A4, CYP3A5, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP2J2. Darunavir is a potent inhibitor of P-glycoprotein. Darunavir is a potent inhibitor of UGT1A1.

**COMMUNICATIONS:** The safety and efficacy of the use of PREZISTA/ritonavir in children is limited. Darunavir/ritonavir has not been studied in children <3 years of age. Use with caution when used in children with severe liver disease. Clinical pharmacokinetic interaction studies between darunavir/ritonavir and HIV-1 protease inhibitors have been performed. Darunavir is a potent inhibitor of CYP3A4. Darunavir is a moderate inhibitor of CYP1A2 and CYP3A4. Darunavir is a potent inhibitor of CYP2C9 and CYP2C19. Darunavir is a moderate inhibitor of CYP2D6, CYP2E1 and CYP2J2. Darunavir is a weak inhibitor of CYP2C8, CYP2C18, CYP2C19 and CYP2D6. Darunavir does not inhibit CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2F2, CYP2G1, CYP3A4, CYP3A5, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP2J2. Darunavir is a potent inhibitor of P-glycoprotein. Darunavir is a potent inhibitor of UGT1A1.

**ADVERSE REACTIONS:** Adverse events should be reported. Forming reports and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Ltd on 01444 567467.
Badges must be worn at all times in order to gain access to the lecture theatre, exhibition and dining areas

VENUES AND LOCATIONS

All locations are Manchester Central Convention Complex, unless stated otherwise

- Registration: Exchange Foyer, Level One
- Lecture Theatre: Exchange Auditorium, Level One
- Exhibition: Exchange Hall, Level One
- Posters: Exchange Hall, Level One
- Lunch and Refreshments: Exchange Hall, Level One
- BHIVA Lunchtime Workshops: One, Three, Five: Exchange Room 1, Level Two
- BHIVA Lunchtime Workshops: Two, Four, Six: Exchange Rooms 6–7, Level Two
- Satellite Symposia: Exchange Auditorium, Level One
- Sponsors’ Workshops: Exchange Rooms 4–5, Level Two
- Speakers’ Preview Room: Exchange Room 2, Level Two
- Sponsors’ Rehearsal Room: Exchange Room 4, Level Two
- Civic Welcome Reception: Exchange Hall, Level One
- Gala Dinner: The Monastery

18 CPD Credits Unique reference number: 79391
# COMMITTEES

## EXECUTIVE COMMITTEE

<table>
<thead>
<tr>
<th>OFFICERS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair</strong></td>
</tr>
<tr>
<td>Prof J Anderson</td>
</tr>
<tr>
<td><strong>Honorary Secretary</strong></td>
</tr>
<tr>
<td>Dr AJ Palfreeman</td>
</tr>
<tr>
<td><strong>Honorary Treasurer</strong></td>
</tr>
<tr>
<td>Prof C Leen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEMBERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr D Asboe</td>
</tr>
<tr>
<td>Dr S Bhagani</td>
</tr>
<tr>
<td>Mr G Brough</td>
</tr>
<tr>
<td>Dr D Churchill</td>
</tr>
<tr>
<td>Dr A de Ruiter</td>
</tr>
<tr>
<td>Dr C Emerson</td>
</tr>
<tr>
<td>Dr MJ Fisher</td>
</tr>
<tr>
<td>Dr AR Freedman</td>
</tr>
<tr>
<td>Prof BG Gazzard</td>
</tr>
<tr>
<td>Prof S Khoo</td>
</tr>
<tr>
<td>Dr RB Kulasegaram</td>
</tr>
<tr>
<td>Dr A Miller</td>
</tr>
<tr>
<td>Dr MR Nelson</td>
</tr>
<tr>
<td>Dr ELC Ong</td>
</tr>
<tr>
<td>Dr K Rogstad</td>
</tr>
<tr>
<td>Prof C Sabin</td>
</tr>
<tr>
<td>Dr EGL Wilkins</td>
</tr>
</tbody>
</table>

## CONFERENCES SUBCOMMITTEE

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr David Asboe</td>
<td>Chair</td>
</tr>
<tr>
<td>Mr Garry Brough</td>
<td>BHIVA Executive Committee member and Community Representative</td>
</tr>
<tr>
<td>Dr Annemieke de Ruiter</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr Carol Emerson</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr Martin Fisher</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr Ranjababu Kulasegaram</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Prof Clifford Leen</td>
<td>BHIVA Honorary Treasurer</td>
</tr>
<tr>
<td>Dr Alastair Miller</td>
<td>Vice Chair</td>
</tr>
<tr>
<td>Dr Mark Nelson</td>
<td>BHIVA Education and Scientific Subcommitte Chair</td>
</tr>
<tr>
<td>Dr Alastair Miller</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr Karen Rogstad</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr Laura Waters</td>
<td>Invited Representative</td>
</tr>
<tr>
<td>Dr Ed Wilkins</td>
<td>Local Host, Manchester 2013</td>
</tr>
</tbody>
</table>

## ORAL RESEARCH JUDGING PANEL

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Alastair Miller</td>
<td>Chair</td>
</tr>
<tr>
<td>Dr Alec Bonington</td>
<td>Local Representative</td>
</tr>
<tr>
<td>Mr Simon Collins</td>
<td>Invited Representative</td>
</tr>
<tr>
<td>Dr Carol Emerson</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr Annemieke de Ruiter</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr Colm O’Mahony</td>
<td>Local Representative</td>
</tr>
<tr>
<td>Dr Ed Ong</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr Ed Wilkins</td>
<td>Local Host, Manchester 2013</td>
</tr>
</tbody>
</table>

## POSTER PRESENTATION JUDGING PANEL

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Andrew Freedman</td>
<td>Chair</td>
</tr>
<tr>
<td>Dr David Asboe</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr Tom Blanchard</td>
<td>Local Representative</td>
</tr>
<tr>
<td>Prof Mark Bower</td>
<td>Invited Representative</td>
</tr>
<tr>
<td>Mr Garry Brough</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr Duncan Churchill</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr Karen Rogstad</td>
<td>BHIVA Executive Committee member</td>
</tr>
<tr>
<td>Dr Laura Waters</td>
<td>Invited Representative</td>
</tr>
</tbody>
</table>
## TUESDAY 16 APRIL

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1700–2000</td>
<td>Registration open at Manchester Central Convention Complex</td>
</tr>
<tr>
<td>1730–2000</td>
<td>BHIVA New Consultants Forum</td>
</tr>
</tbody>
</table>

## WEDNESDAY 17 APRIL

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800–2000</td>
<td>Registration and Exhibition open at Manchester Central Convention Complex</td>
</tr>
<tr>
<td>0855–0900</td>
<td>Welcome Address</td>
</tr>
<tr>
<td>0900–1000</td>
<td>AbbVie Satellite Symposium</td>
</tr>
<tr>
<td>1000–1100</td>
<td>Janssen Satellite Symposium</td>
</tr>
<tr>
<td>1100–1120</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1120–1220</td>
<td>Gilead Sciences Satellite Symposium</td>
</tr>
<tr>
<td>1220–1230</td>
<td>Welcome Address</td>
</tr>
<tr>
<td>1230–1300</td>
<td>BHIVA Review Session</td>
</tr>
<tr>
<td>1300–1500</td>
<td>Lunch, Workshops and Poster Presentations</td>
</tr>
<tr>
<td>1310–1355</td>
<td>BHIVA Lunchtime Workshops 1 and 2</td>
</tr>
<tr>
<td>1355–1455</td>
<td>Janssen Lunchtime Workshop</td>
</tr>
<tr>
<td>1500–1530</td>
<td>BHIVA Keynote Lecture</td>
</tr>
<tr>
<td>1530–1630</td>
<td>Oral Research Presentations: Session 1</td>
</tr>
<tr>
<td>1630–1700</td>
<td>Afternoon tea</td>
</tr>
<tr>
<td>1700–1800</td>
<td>BHIVA Invited Lectures</td>
</tr>
<tr>
<td>1800–1900</td>
<td>Bristol-Myers Squibb Pharmaceuticals Satellite Symposium</td>
</tr>
<tr>
<td>1900–2000</td>
<td>Civic Welcome Reception</td>
</tr>
</tbody>
</table>

## THURSDAY 18 APRIL

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0745–1830</td>
<td>Registration and Exhibition open at Manchester Central Convention Complex</td>
</tr>
<tr>
<td>0800–0855</td>
<td>Janssen Breakfast Workshop</td>
</tr>
<tr>
<td>0900–1000</td>
<td>MSD Satellite Symposium</td>
</tr>
<tr>
<td>1000–1100</td>
<td>BHIVA Guidelines Session</td>
</tr>
<tr>
<td>1100–1124</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1124–1300</td>
<td>Oral Research Presentations: Session 2</td>
</tr>
<tr>
<td>1300–1500</td>
<td>Lunch, Workshops and Poster Presentations</td>
</tr>
<tr>
<td>1310–1355</td>
<td>BHIVA Lunchtime Workshops 3 and 4</td>
</tr>
<tr>
<td>1355–1455</td>
<td>Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop</td>
</tr>
<tr>
<td>1500–1636</td>
<td>Oral Research Presentations: Session 3</td>
</tr>
<tr>
<td>1636–1700</td>
<td>Afternoon tea</td>
</tr>
<tr>
<td>1700–1730</td>
<td>BHIVA Audit Session</td>
</tr>
<tr>
<td>1730–1830</td>
<td>BHIVA Plenary Session 1</td>
</tr>
<tr>
<td>2000–0030</td>
<td>Gala Dinner: The Monastery</td>
</tr>
</tbody>
</table>

## FRIDAY 19 APRIL

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0830–1430</td>
<td>Registration and Exhibition open at Manchester Central Convention Complex</td>
</tr>
<tr>
<td>0900–1000</td>
<td>BHIVA Clinico-pathological SpR case presentations</td>
</tr>
<tr>
<td>1000–1030</td>
<td>MRC Clinical Trials Unit Session</td>
</tr>
<tr>
<td>1030–1100</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1100–1200</td>
<td>Oral Research Presentations: Session 4</td>
</tr>
<tr>
<td>1200–1230</td>
<td>Oral Research Poster Presentations</td>
</tr>
<tr>
<td>1230–1430</td>
<td>Lunch, Workshops and Poster Presentations</td>
</tr>
<tr>
<td>1240–1325</td>
<td>BHIVA Lunchtime Workshops 5 and 6</td>
</tr>
<tr>
<td>1325–1425</td>
<td>Gilead Sciences Lunchtime Workshop</td>
</tr>
<tr>
<td>1430–1445</td>
<td>BHIVA Prizes and Awards Ceremony</td>
</tr>
<tr>
<td>1445–1545</td>
<td>BHIVA Plenary Session 2</td>
</tr>
<tr>
<td>1545–1615</td>
<td>BHIVA Debate</td>
</tr>
<tr>
<td>1615</td>
<td>Close</td>
</tr>
</tbody>
</table>
## Tuesday 16 April 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1700–2000</td>
<td>Registration open at Manchester Central Convention Complex</td>
</tr>
<tr>
<td>1730–2000</td>
<td><strong>BHIVA New Consultants Forum</strong> Exchange Room 6, Level Two</td>
</tr>
<tr>
<td>1730–1745</td>
<td><strong>Welcome</strong></td>
</tr>
<tr>
<td></td>
<td>Dr David Asboe</td>
</tr>
<tr>
<td></td>
<td><em>Chelsea and Westminster Hospital, London</em></td>
</tr>
<tr>
<td></td>
<td>Dr Carol Emerson</td>
</tr>
<tr>
<td></td>
<td><em>The Royal Hospitals, Belfast</em></td>
</tr>
<tr>
<td>1745–1825</td>
<td><strong>Being a new consultant: the challenges and opportunities</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Caroline Fryar</td>
</tr>
<tr>
<td></td>
<td><em>The Medical Defence Union Limited</em></td>
</tr>
<tr>
<td>1825–1905</td>
<td><strong>Commissioning in HIV</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Anton Pozniak</td>
</tr>
<tr>
<td></td>
<td><em>Chelsea and Westminster Hospital, London</em></td>
</tr>
<tr>
<td>1905–1945</td>
<td><strong>A user’s guide to job planning</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Colm O’Mahony</td>
</tr>
<tr>
<td></td>
<td><em>Countess of Chester Hospital</em></td>
</tr>
<tr>
<td>1945–1955</td>
<td><strong>Mentoring update</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Carol Emerson</td>
</tr>
<tr>
<td></td>
<td><em>The Royal Hospitals, Belfast</em></td>
</tr>
<tr>
<td>1955–2000</td>
<td><strong>Close</strong></td>
</tr>
</tbody>
</table>

## Wednesday 17 April 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800–2000</td>
<td>Registration and exhibition open at Manchester Central Convention Complex</td>
</tr>
<tr>
<td>0855–0900</td>
<td><strong>Open by the Chair of the British HIV Association</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Jane Anderson</td>
</tr>
<tr>
<td></td>
<td><em>Homerton University Hospital, London</em></td>
</tr>
<tr>
<td>0900–1000</td>
<td><strong>AbbVie Satellite Symposium</strong></td>
</tr>
<tr>
<td></td>
<td><em>(see page 16 for further details)</em></td>
</tr>
<tr>
<td>1000–1100</td>
<td><strong>Janssen Satellite Symposium</strong></td>
</tr>
<tr>
<td></td>
<td><em>(see page 16 for further details)</em></td>
</tr>
<tr>
<td>1100–1120</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1120–1220</td>
<td><strong>Gilead Sciences Satellite Symposium</strong></td>
</tr>
<tr>
<td></td>
<td><em>(see page 17 for further details)</em></td>
</tr>
<tr>
<td>1220–1230</td>
<td><strong>Welcome Address by the Chair of the British HIV Association</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Jane Anderson</td>
</tr>
<tr>
<td></td>
<td><em>Homerton University Hospital, London</em></td>
</tr>
<tr>
<td>1230–1300</td>
<td><strong>BHIVA Review Session</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Professor Clifford Leen</td>
</tr>
<tr>
<td></td>
<td><em>Western General Hospital, Edinburgh</em></td>
</tr>
<tr>
<td></td>
<td><strong>Five papers to change clinical practice</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Andrew Lever</td>
</tr>
<tr>
<td></td>
<td><em>University of Cambridge</em></td>
</tr>
</tbody>
</table>
### Wednesday 17 April 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1300–1500</td>
<td>Lunch, workshops and poster presentations</td>
</tr>
<tr>
<td>1310–1355</td>
<td><strong>BHIVA Lunchtime Workshop 1</strong> Exchange Room 1, Level Two (see page 20 for further details)</td>
</tr>
<tr>
<td></td>
<td><strong>Difficult pharmacology case presentations</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Dr Marta Boffito&lt;br&gt;Chelsea and Westminster Hospital, London</td>
</tr>
<tr>
<td></td>
<td><strong>Dangerous liaisons</strong>&lt;br&gt;Dr Gurmit Jagit Singh&lt;br&gt;Chelsea and Westminster Hospital, London</td>
</tr>
<tr>
<td></td>
<td><strong>What's the craic?</strong>&lt;br&gt;Dr Leann Johnson&lt;br&gt;North Manchester General Hospital</td>
</tr>
<tr>
<td></td>
<td><strong>To treat or not to treat?: a toxicity dilemma</strong>&lt;br&gt;Dr Keerti Gedela&lt;br&gt;Chelsea and Westminster Hospital, London</td>
</tr>
<tr>
<td>1310–1355</td>
<td><strong>BHIVA Lunchtime Workshop 2</strong> Exchange Room 6–7, Level Two (see page 20 for further details)</td>
</tr>
<tr>
<td></td>
<td><strong>TB /HIV co-infection case presentations</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Dr Andrew Freedman&lt;br&gt;Cardiff University School of Medicine</td>
</tr>
<tr>
<td></td>
<td>Dr Marc Lipman&lt;br&gt;Royal Free Hospital, London</td>
</tr>
<tr>
<td>1355–1455</td>
<td><strong>Janssen Lunchtime Workshop</strong> Exchange Room 4–5, Level Two (see page 17 for further details)</td>
</tr>
<tr>
<td>1500–1530</td>
<td><strong>BHIVA Keynote Lecture</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Dr David Asboe&lt;br&gt;Chelsea and Westminster Hospital, London</td>
</tr>
<tr>
<td></td>
<td><strong>Viral resistance: a look into the crystal ball</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Charles Boucher&lt;br&gt;University Medical Center Utrecht, Netherlands</td>
</tr>
<tr>
<td>1530–1630</td>
<td><strong>Oral Research Presentations: Session 1</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Behaviour, attitudes and testing</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Sanjay Bhagani&lt;br&gt;Royal Free Hospital, London</td>
</tr>
<tr>
<td></td>
<td>Dr Margaret Kingston&lt;br&gt;Central Manchester University Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>1530–1542</td>
<td><strong>Abstract O1</strong>&lt;br&gt;Is primary care prescribing for people with HIV safe? A review of practice in an inner London setting&lt;br&gt;Dr Rosie Wellesley, Barts and The London School of Medicine and Dentistry</td>
</tr>
<tr>
<td>1542–1554</td>
<td><strong>Abstract O2</strong>&lt;br&gt;Increasing opportunities for HIV diagnosis in primary care: a borough-wide evaluation of HIV testing and pre-diagnosis care in general practice&lt;br&gt;Dr Alice Whittle, City and Hackney Public Health Department, London</td>
</tr>
</tbody>
</table>
1554–1606 Abstract O3
CD4 point of care testing improves patient satisfaction and reduces recalls to clinic
Dr Clifford Jones, Imperial College Healthcare NHS Trust, London

1606–1618 Abstract O4
Prevalence of, and risk factors for, human immunodeficiency virus, hepatitis B and hepatitis C infections among men who inject image- and performance-enhancing drugs in England and Wales
Dr Vivian Hope, Health Protection Agency, London

1618–1630 Abstract O5
Psychological and physical symptoms and sexual behaviour among HIV-diagnosed men who have sex with men (MSM) in the UK
Dr Fiona Lampe, University College London

1630–1700 Afternoon tea

1700–1800 BHIVA Invited Lectures
Chairs: Dr Adrian Palfreeman
Leicester Royal Infirmary
Dr Ian Williams
University College London Medical School

Generics: how should we use them?
Dr Mark Nelson
Chelsea and Westminster Hospital, London

BHIVA is grateful for an educational grant in support of this lecture from Boehringer Ingelheim
Please see page 20 for further details

Towards a cure
Dr Romas Geleziunas
Gilead Sciences Inc, USA

1800–1900 Bristol-Myers Squibb Pharmaceuticals Satellite Symposium (see page 17 for further details)

1900–2000 Civic Welcome Reception (see page 23 for further details)
Exchange Hall, Level One, Manchester Central Convention Complex
Chair by the Conference Local Host
Dr Ed Wilkins
North Manchester General Hospital

Councillor Elaine Boyes
The Right Worshipful, The Lord Mayor of the City of Manchester

Lord Norman Fowler
Patron, British HIV Association (BHIVA)

Professor Jane Anderson
Chair, British HIV Association (BHIVA)
THURSDAY 18 APRIL 2013

0745–1830 Registration and exhibition open at Manchester Central Convention Complex

All sessions will be held in Exchange Auditorium unless otherwise stated

0800–0855 Janssen Breakfast Workshop Exchange Room 4–5, Level Two (see page 18 for further details)

0900–1000 MSD Satellite Symposium (see page 18 for further details)

1000–1045 BHIVA Guidelines Session
Chairs: Dr Martin Fisher
Brighton and Sussex University Hospitals NHS Trust
Dr Chloe Orkin
Barts Health NHS Trust, London

BHIVA guidelines for the management of co-infection with HIV-1 and hepatitis viruses
Dr Ed Wilkins
North Manchester General Hospital

BHIVA guidelines for the treatment of malignancies in HIV-positive individuals
Professor Mark Bower
Chelsea and Westminster Hospital, London

1045–1100 BHIVA Special General Meeting

1100–1124 Morning coffee

1124–1300 Oral Research Presentations: Session 2
HIV co-infections and complications
Chairs: Dr Ranjababu Kulasegaram
St Thomas’ Hospital, London
Dr Mark Nelson
Chelsea and Westminster Hospital, London

1124–1136 Abstract O6
Occult hepatitis B/HIV co-infection in African migrants to the UK: a point prevalence study
Dr David Chadwick, James Cook University Hospital, Middlesbrough

1136–1148 Abstract O7
HCV reinfection incidence among HIV-positive men who have sex with men
Dr Thomas Martin, Chelsea and Westminster Hospital, London

1148–1200 Abstract O8
Alterations in the balance of Th1 (CXCR3+CCR5+) cells to Th17 (CCR4+CCR6+CCR10−) and Th22 (CCR4+CCR6+CCR10+) cells in HIV-1/HCV co-infection is associated with immune activation, microbial translocation and liver fibrosis
Dr Emma Page, Imperial College London

1200–1212 Abstract O9
Quantification of hepatic FOXP3+ T-lymphocytes in HIV-hepatitis C co-infection: a mechanism for poor outcomes?
Dr Sion Williams, Brighton and Sussex University Hospitals

1212–1224 Abstract O10
Impact of screening on staging and survival of hepatocellular carcinoma (HCC) in HIV/HCV coinfected patients
Dr Emma Page, Chelsea and Westminster Hospital, London
THURSDAY 18 APRIL 2013

1224–1236 Abstract O11
The effect of antiretroviral therapy on chest radiograph appearance in HIV-associated pulmonary tuberculosis
Dr Clare van Halsema, North Manchester General Hospital

1236–1248 Abstract O12
Effects of renal tubular dysfunction on bone in HIV-positive patients
Dr Amanda Samarawickrama, Brighton and Sussex University Hospitals

1248–1300 Abstract O13
Value of 18F-FDG PET/CT in HIV-positive patients with neurological presentations
Dr Keerti Gedela, Chelsea and Westminster Hospital NHS Foundation Trust, London

1300–1500 Lunch, workshops and poster presentations

1310–1355 BHIVA Lunchtime Workshop 3 Exchange Room 1, Level Two (see page 20 for further details)
Spot diagnosis: tropical STIs
Chair: Dr John Sweeney
NHS Blackpool
Professor David Mabey
London School of Hygiene and Tropical Medicine

1310–1355 BHIVA Lunchtime Workshop 4 Exchange Room 6–7, Level Two (see page 20 for further details)
HIV and chronic diarrhoea: case presentations
Chair: Dr Carol Emerson
The Royal Hospitals, Belfast
Dr Andrew Ustianowski
North Manchester General Hospital

1355–1455 Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop
Exchange Room 4–5, Level Two (see page 18 for further details)

1500–1636 Oral Research Presentations: Session 3
Pregnancy, gender and transmission
Chairs: Dr Katherine Ajdukiewicz
North Manchester General Hospital
Dr Annemiek de Ruiter
St Thomas’ Hospital, London

1500–1512 Abstract O14
Does initiation of highly active antiretroviral therapy (HAART) before pregnancy increase risk of adverse outcomes: miscarriage, prematurity, stillbirth?
Dr Helen Dale, University Hospitals Birmingham

1512–1524 Abstract O15
Elevated leukocyte adhesion marker VCAM-1 in HIV-1-infected in women initiating PI-based ART during pregnancy compared to women conceiving on PI-based ART and women initiating triple-NRTI ART
Dr Charlotte-Eve Short, Imperial College London

1524–1536 Abstract O16
Loss to follow-up after pregnancy among women living with HIV in England, Wales and Northern Ireland: the role of African ethnicity
Dr Shema Tariq, City University London
1536–1548 Abstract O17
Gender differences in outcomes to first-line treatment in the era of modern antiretroviral therapy (ART)
Dr Peter Saunders, Royal Free London NHS Foundation Trust

1548–1600 Abstract O18
Mental health diagnoses in HIV-infected young people: an HIV Young Persons Network audit
Dr Ellen Dwyer, Croydon University Hospital

1600–1612 Abstract O19
Intimate partner violence in male and female patients living with HIV
Dr Sian Warren, Cardiff Royal Infirmary

1612–1624 Abstract O20
Continued high levels of condomless sex in serodifferent couples when the positive partner is on antiretroviral therapy: the PARTNER study
Dr Alison Rodger, University College London

1624–1636 Abstract O21
Reducing onward transmission: viral suppression among key population groups living with HIV in the United Kingdom
Dr Valerie Delpech, Health Protection Agency, London

1636–1700 Afternoon tea

1700–1730 BHIVA Audit Session
Chair: Dr Ed Ong
Royal Victoria Infirmary, Newcastle
Audit of people with diagnosed HIV infection not attending for care
Dr Katherine Clay
Birmingham Heartlands Hospital

1730–1830 BHIVA Plenary Session 1: The virtual clinic
Chairs: Dr Simon Edwards
University College London Medical School
Professor Margaret Johnson
Royal Free Hospital, London
Haemophagocytosis syndrome (HPS) in HIV
Dr Nadia Ahmed
Mortimer Market Centre, London
HIV/hepatitis co-infection in pregnancy
Dr Aoife Molloy
Royal Free Hospital, London
Drug–drug interactions in renal transplantation
Dr Anna Goodman
Royal Free Hospital, London
Expert Panel
Dr Jonathan Ainsworth
North Middlesex University Hospital
Professor Clifford Leen
Western General Hospital, Edinburgh
Dr Marta Boffito
Chelsea and Westminster Hospital, London

2000–0030 Drinks Reception and Gala Dinner (see page 23 for further details)
The Monastery
FRIDAY 19 APRIL 2013

0830–1430 Registration and exhibition open at Manchester Central Convention Complex

All sessions will be held in Exchange Auditorium unless otherwise stated

0900–1000 BHIVA Clinico-pathological SpR case presentations
Chair: Professor Sebastian Lucas
St Thomas’ Hospital, London

Stop the press: an uncommon presentation of hypercalcaemia
Dr James Stevenson
King’s College Hospital, London

A swell ‘d8’
Dr Emily Chung
Mortimer Market Centre, London

Expecting the unexpected
Dr Anna Hartley
Barts Health NHS Trust, London

A multi-system syndrome: is it the drug or is it a bug?
Dr John Thornhill
Barts Health NHS Trust, London

1000–1030 MRC Clinical Trials Unit Session
Neurocognitive testing in HIV clinical trials
Chair: Dr Nick Paton
MRC Clinical Trials Unit, London

Neurocognitive testing in clinical trials: luxury or necessity?
Dr Alan Winston
Imperial College Healthcare NHS Trust, London

Neurocognitive test results from contemporary trials: what do they tell us?
Dr Alejandro Arenas-Pinto
University College London

1030–1100 Morning coffee

1100–1200 Oral Research Presentations: Session 4
Antiretroviral treatment
Chairs: Dr Duncan Churchill
Brighton and Sussex University Hospitals NHS Trust
Professor Caroline Sabin
Royal Free and University College London Medical School

1100–1112 Abstract O22
The feasibility of switching efavirenz (EFV)-based highly active antiretroviral therapy to raltegravir (RAL)-based therapy in HIV-infected individuals with central nervous system (CNS) toxicity: a Phase IV open label pilot study
Dr Manisha Yapa, Chelsea and Westminster Hospital, London

1112–1124 Abstract O23
Impairment of renal function associated with tenofovir therapy in HIV-infected patients
Miss Kirsty McKelvey, University of Edinburgh
FRIDAY 19 APRIL 2013

1124–1136  Abstract O24
HIV-1 RNA and HIV-1 DNA persistence during long-term suppressive ART
Professor Anna Maria Geretti, University of Liverpool

1136–1148  Abstract O25
Therapeutic immunisation in conjunction with IL-2, GM-CSF and rhGH improves CD4 T-cell counts and reduces immune activation in cART-treated HIV-1+ patients: a Phase I clinical study
Dr Anna Herasimtschuk, Imperial College London

1148–1200  Abstract O26
Therapeutic tendering: an innovative strategy to reduce the cost of antiretroviral therapy
Dr Paul Benn, Central and North West London NHS Foundation Trust

1200–1230  Oral Poster Presentations
Chairs: Dr Andrew Freedman
Cardiff University School of Medicine
Dr Alastair Miller
Royal Liverpool University Hospital

1230–1430  Lunch, workshops and poster presentations

1240–1325  BHIVA Lunchtime Workshop 5  Exchange Room 1, Level Two  (see page 20 for further details)
ART and toxicity case presentations
Chairs: Professor Saye Khoo
University of Liverpool
Dr Cal Cohen
Harvard Medical School, Boston, USA

Infection, inflammation or injury?
Dr Stuart Flanagan
Homerton University Hospital, London

Doctor! Is it my lifestyle or the infection causing problems?
Dr Dawn Friday
Warrington General Hospital

Does ART for all mean OLT for all?
Dr Endip Dhesi
Royal Free Hospital, London

1240–1325  BHIVA Lunchtime Workshop 6  in collaboration with the National HIV Nurses Association (NHIVNA)  Exchange Room 6–7, Level Two
Multidisciplinary team working: the role of the Advanced Practice Nurse in the MDT
Invited consultation meeting to discuss the nurse’s role in the clinical team, with an aim to producing guidelines on Advanced Nursing Practice (ANP) in June 2013.
Chair: Ms Jane Bruton
Chelsea and Westminster Hospital, London

Defining the Advanced Practice Nursing Role
Mr Nathaniel Ault
Barts Health NHS Trust, London

Round table discussions
- How it fits within the MDT
- Essential support for the role
- Educational attainment and competencies
- Leading on outcomes, including audit and research
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1325–1425</td>
<td><strong>Gilead Sciences Lunchtime Workshop</strong> Exchange Room 4–5, Level Two</td>
<td>(see page 18 for further details)</td>
</tr>
<tr>
<td>1430–1445</td>
<td><strong>BHIVA Prizes and Awards Ceremony</strong></td>
<td></td>
</tr>
<tr>
<td>1445–1545</td>
<td><strong>BHIVA Plenary Session 2</strong></td>
<td></td>
</tr>
</tbody>
</table>
|          | Chairs: Dr Karen Rogstad  
                  | *Royal Hallamshire Hospital, Sheffield*  
                  | Dr Andrew Ustianowski  
                  | *North Manchester General Hospital* |                                    |
|          | **Where to next with HPV vaccination? New strategies, new vaccines** |                                    |
|          | Professor Margaret Stanley  
                  | *University of Cambridge*            |                                    |
|          | **Can we live without nucleosides?**               |                                    |
|          | Professor José Arribas  
                  | *Hospital La Paz, Madrid, Spain*     |                                    |
| 1545–1615 | **BHIVA Debate**                                   |                                    |
|          | Chair: Dr Ed Wilkins  
                  | *North Manchester General Hospital*  |                                    |
|          | **The motion: Antiretroviral treatment should be routinely commenced at a CD4 count of 500** |                                    |
|          | **For the motion:**                                |                                    |
|          | Dr Cal Cohen  
                  | *Harvard Medical School, Boston, USA* |                                    |
|          | **Against the motion:**                            |                                    |
|          | Professor Caroline Sabin  
                  | *Royal Free and University College London Medical School* |                                    |
| 1615     | **Close by the Chair of the British HIV Association** |                                    |
|          | Professor Jane Anderson  
                  | *Homerton University Hospital, London* |                                    |
At your service

Developing health and social support systems for women living with HIV

Tuesday 21 May 2013
18:00 – 21:00
Renaissance Hotel, Manchester
Registration Now Open

This educational meeting aims to provide practical advice on developing enhanced, holistic HIV and women’s services in the era of Quality, Innovation, Productivity and Prevention, and will explore:

- what is required to deliver holistic, patient-centric HIV and women’s services
- practical advice on how to develop such services
- insights into service development from the perspective of the clinical director and finance director

Speakers

Chair: Dr Margaret Kingston
Consultant, Central Manchester University Hospital
Professor Margaret Johnson
Clinical Director/Consultant, Royal Free Hospital, London
Lynda Shentall
Director of Services, George House Trust, Manchester

Audience

Those with a responsibility for caring for women living with HIV including physicians, nurses, pharmacists, social care workers, and those with management and budgetary responsibilities

To register your interest to attend please contact the event secretariat:
Sayeed Anwar
sanwar@chandlerchicccompanies.com
Tel: 020 7632 1906

At your service is sponsored by AbbVie
All satellite symposia will be held in Exchange Auditorium, Level One and Sponsors’ Workshops will be held in Exchange 4–5, Level Two.

0900–1000  AbbVie Satellite Symposium

Therapeutic sequencing: does it have a place in the life-long management of HIV?
Long-term therapeutic modelling in HIV - a realistic goal?
Dr Mike Youle
Royal Free Hospital, London

Show me the child and I’ll show you the man
Dr Graham Taylor
St Mary’s Hospital, London

Modelling management strategies avoiding intolerance or resistance: what are the options … that leave you the most options?
Professor Saye Khoo
Royal Liverpool University Hospital

Choose your armamentarium for old age with HIV
Dr Mike Youle
Royal Free Hospital, London

1000–1100  Janssen Satellite Symposium

HIV: a positive future?
Chair: Mr David Thorne
Former Chief Executive NHS Newcastle West CCG

Responding to the changing environment: an HIV clinician’s perspective
Dr Mark Pakianathan
St George’s Hospital, London

Patient perspective: hopes and fears
Ms Angelina Namiba
Patient representative

What about us: what does the future look like for healthcare providers?
Ms Nicky Perry
Brighton and Sussex University Hospitals NHS Trust

Commissioning for specialised HIV care and treatment
Ms Claire Foreman
London Specialised Commissioning Group
SATELLITE SYMPOSIA AND SPONSORS’ LUNCHTIME WORKSHOPS

WednesDay 17 April 2013

All satellite symposia will be held in Exchange Auditorium, Level One and Sponsors’ Workshops will be held in Exchange 4–5, Level Two

1120–1220

Gilead Sciences Satellite Symposium

The evolving landscape of HIV therapy: a debate

Chair: Dr Simon Barton
Chelsea and Westminster Hospital, London

Treatment as prevention in the UK: not enough evidence yet?
Dr Andrew Ustianowski
North Manchester General Hospital

Dr John White
Guy’s and St Thomas’ NHS Foundation Trust, London

Is efavirenz still the gold standard treatment in HIV?
Dr Martin Fisher
Brighton and Sussex University Hospitals NHS Trust

Dr Nicola Mackie
Imperial College Healthcare NHS Trust, London

Single-tablet regimens represent more value than multiple-tablet regimens
Dr Andrew Ustianowski
North Manchester General Hospital

Dr John White
Guy’s and St Thomas’ NHS Foundation Trust, London

1355–1455

Janssen Lunchtime Workshop

Embracing Change: An Integrated Care Pathway

Introduction to the HIV integrated care pathway (ICP) workshop
Dr Ed Ong
Royal Victoria Infirmary, Newcastle

Defining an integrated care pathway
Dr Simon Gwynn
Health Service Consultant, Triducive

What can an integrated care pathway deliver?
Dr Peter Hoare
Consultant Child & Adolescent Psychiatrist and Clinical Lead, Herefordshire

An integrated care pathway for HIV
Ms Nicky Perry
Sussex University Hospital NHS Trust

1800–1900

Bristol-Myers Squibb Pharmaceuticals Medical Educational Satellite Symposium

What is success in long-term HIV care?
Chair: Dr Chloe Orkin
Barts Health NHS Trust, London

Benchmarking HIV care for the future
Dr Anton Pozniak
Chelsea and Westminster Hospital, London

Comorbidities in long-term HIV care
Dr Paddy Mallon
Mater Misericordiae University Hospital, Dublin
SATELLITE SYMPOSIA AND SPONSORS’ LUNCHTIME WORKSHOPS

THURSDAY 18 APRIL 2013

0800–0855  Janssen Breakfast Workshop
Using rilpivirine in the treatment-naïve setting: with case study discussions
Dr Laura Waters
Mortimer Market Centre, London

0900–1000  MSD Satellite Symposium
A new commissioning landscape: where does the patient fit?
Chair: Dr Ian Williams
University College London Medical School
Commissioning and the changing NHS: what is intended to happen and what is really happening?
Mr Graham Atkinson
Director of Transformation and Commissioning, Soar Beyond Ltd
Commissioning HIV services: what does the change in commissioning mean for HIV and the HIV patient experience?
Mr Steve Callaghan
Principal Consultant, EQE Health Ltd
What do patients want?
Mr Robert Fieldhouse
BASELINE

1355–1455  Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop
New data and key issues in the treatment of HIV-positive women
Update from International Women’s Workshop and CROI
Professor Margaret Johnson
Royal Free Hospital, London
Patient and Healthcare Professional (HCP) dialogue role play
Dr Carol Emerson
The Royal Hospitals, Belfast
Ms Zoë Sheppard
Chelsea and Westminster Hospital, London
Ms Thandi Haruperi
Restor Ego

FRIDAY 19 APRIL 2013

1325–1425  Gilead Sciences Lunchtime Workshop
ART to reduce HIV transmission
Chair: Dr David Asboe
Chelsea and Westminster Hospital, London
Physician perspective
Dr Martin Fisher
Brighton and Sussex University Hospitals NHS Trust
Policy perspective
Dr Yusef Azad
National AIDS Trust
Patient perspective
Mr Robert Fieldhouse
BASELINE
EXHIBITION FLOOR PLAN AND EXHIBITORS

Exchange Hall · Manchester Central Convention Complex

Key to Exhibitors

1 Marie Stopes International
2 6PM Healthcare Ltd
3 Boehringer Ingelheim Ltd
4 ViiV Healthcare UK Ltd
5 BASELINE
6 George House Trust
7 Alcura Ltd
8 Gilead Sciences Ltd
9 Janssen
10 HIV Pharmacy Association (HIVPA)
11 Children’s HIV Association (CHIVA)
12 Bristol-Myers Squibb Pharmaceuticals Ltd
13 UK Community Advisory Board (UK-CAB) / HIV i-Base
14 National HIV Nurses Association (NHIVNA)
15 Justri (The Training and Resource Initiative)
16 Blithe Computer Systems Ltd
17 Galen Ltd
18 AbbVie Ltd
19 Healthcare at Home Ltd
20 ffena Network of AHPN
21 Bristol-Myers Squibb Pharmaceuticals Virology Partnership
22 MSD Ltd
23 Dietitians working in HIV/AIDS (DHIVA) / Rehabilitation HIV Association (RHIVA)
24 The Sophia Forum
25 Terrence Higgins Trust (THT)
26 Saving Lives
27 Positively UK
28 Centre for All Families Positive Health (CAFPH)
29 National AIDS Trust
30 NAM
31 QIAGEN Ltd
32 Evolution Homecare
Registration

Registration includes access to all scientific sessions, including satellite symposia, the exhibition area, refreshments and lunch for the days specified in your registration acknowledgement correspondence.

Delegate badges

Badges must be worn at all times to gain access to the lecture theatre, catering and exhibition areas. The delegate lanyards have been sponsored by Gilead Sciences.

Accompanying persons Pre-booked and paid only

Accompanying persons’ fees include attendance at the Civic Welcome Reception and Gala Dinner. Each event is individually priced. These tickets must have been requested and paid for in advance of the conference. Please note that these fees do not cover attendance at the scientific sessions, exhibition or catering areas of the conference.

BHIVA Lunchtime workshops

Places are limited and will be restricted to 80 delegates per workshop. Places will be available onsite, on a first-come, first-served basis, at the door of the lunchtime workshop. Doors will open 15 minutes prior to the start of each workshop. Each workshop will begin promptly and lunch packs will be provided for delegates attending these sessions.

BHIVA Invited Lectures supported by travel bursary grants

With the recent changes to the format of BHIVA conferences, including starting later in the day, finishing earlier in the evening and extending the duration of lunch breaks, BHIVA has replaced the previous sponsored Invited Lecture format with a new arrangement of BHIVA Invited Lectures, which will be supported by means of a travel bursary kindly donated by BHIVA sponsors. All correspondence and liaison with the speakers invited to participate in these sessions has been administered by BHIVA and the speakers are under no obligation to the sponsoring company. Donated travel bursaries will go towards supporting the honorarium, travel and accommodation of the speaker. The slots are entirely educational in content and form part of the BHIVA plenary programme, and thus qualify for CPD accreditation.

BHIVA New Consultants Forum

The BHIVA Young Consultants Forum will bring together young UK consultants (first 5 years of substantive consultant post, to include those in early locum post and/or those within 6 months of CCT) to discuss topics of mutual interest, to raise issues of concern and to provide feedback on these matters to the BHIVA Executive Committee. The Forum will run from 1730–2000 on Tuesday 16 April 2013 followed by dinner. It will comprise four forums, each devoted to a specific theme or topic. Places are limited and in principle have been made available on a first-come, first-served basis.

Continuing Professional Development (CPD)

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will be entitled to receive CPD credits at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, pharmaceutical-supported sessions and social events). The unique reference code for the conference is 79391. The entire conference has been allocated 18 CPD credits. Please be advised that the attendance list of the conference will be forwarded to the Royal College of Physicians upon request.
Social events

There are two organised social events: the Civic Welcome Reception and Gala Dinner. You will require a ticket to gain entry to the Gala Dinner. Please refer to page 23 of this programme for full details of the social events. If you have reserved a ticket but find that you cannot attend, please let the Conference Organiser know as soon as possible and return your ticket to the Registration Desk at your earliest convenience.

Posters

All poster boards will be numbered and poster presenters should use the board displaying the number allocated to their poster. There will be three lunchtime poster sessions between Wednesday and Friday. All poster presenters should be available by their poster for the final 30 minutes of the Wednesday and Thursday lunchtime sessions for potential discussion with delegates and poster judges. The poster judges will review the posters and subsequently select 15 posters to be highly commended, out of which six will be presented as part of the Oral Research Poster Presentations session at 1200–1230 on Friday 19 April. Poster presenters are required to prepare a few slides prior to the conference to highlight the main points of their poster. We would encourage all poster presenters to check the Registration notice board at 1700 on Thursday 18 April to see whether they have been selected. The Ian Williams Best Poster prize will be awarded at the Prizes and Awards Ceremony on Friday 19 April at 1430–1445.

Oral research presentations

Oral research presenters are reminded to ensure they bring their oral research presentation slides to the conference in addition to sending them to the Conference Organisers in advance. Any slides must be passed to the audio-visual technicians in the Speakers’ Preview Room located in Hall 3 Foyer in good time for their session (minimum 3 hours in advance). Oral research presenters may make use of the Speakers’ Preview Room to review their slides prior to presentation. The Margaret Johnson Best Oral Presentation prize will be awarded at the Prizes and Awards Ceremony on Friday 19 April at 1430–1445.

Accommodation

Please note that the registration fee does not include accommodation. If you have not already done so, you can arrange accommodation by contacting Visit Manchester 0161 238 4563 or by following the link on the conference website (www.bhiva.org).

WiFi and internet café

Free WiFi access will be available at the conference centre in Exchange Hall (exhibition hall).

Cloakroom

A manned cloakroom is available onsite in the lower foyer area at Manchester Central Convention Complex. All belongings are left at the owner’s risk. The British HIV Association do not accept responsibility for the loss of, or damage to, delegates’ personal property stored in the cloakroom area.

Exhibition

The exhibition represents an integral element of the conference, providing participants with an excellent platform for networking as well as an opportunity to gain further insight into cutting-edge technology, the latest healthcare solutions, and services within the field of HIV and GU medicine. Entrance to the exhibition hall is free for all registered delegates.

Filming and photography

Please note that all sessions held in the Exchange Auditorium will be filmed and uploaded to the BHIVA website following the event. In addition, some still photography will take place at the conference. This will include general coverage of registration, exhibition and workshop areas, as well as conference social events. This material may be published either in BHIVA publications or on the BHIVA website.
SCHOLARSHIPS AND AWARDS

The Margaret Johnson Best Oral Research Presentation
This prize will be awarded to the presenter of the best oral research presentation during the conference. All oral research presentations will be judged by a BHIVA-appointed oral research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 19 April.

The Ian Williams Best Poster Presentation
This prize will be awarded to the presenter of the best poster research presentation during the conference. All poster research presentations will be judged by a BHIVA-appointed poster research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 19 April.

Best SpR Case Presentation
This prize will be awarded to the presenter of the best case presentation as part of the Clinico-pathological SpR case presentation session. The prize will be presented at the Prizes and Awards Ceremony on Friday 19 April.

Commended Oral Presentations
Up to three awards will be presented in recognition of the best oral research presentations during the conference. All oral presentations will be judged by a BHIVA-appointed oral research judging panel. To be eligible for these awards, presenters must be of junior grade (sub-consultant or equivalent). The commendations will be acknowledged during the Prizes and Awards Ceremony on Friday 19 April.

Commended Poster Presentations
Up to 15 awards will be awarded in recognition of the best poster research presentations during the conference. All poster research presentations will be judged by a BHIVA-appointed poster research judging panel. The commendations will be awarded in the poster area at 1700 on Thursday 18 April.

Mediscript Awards in collaboration with BHIVA
Two prizes will be awarded for the best oral or poster research presentations during the conference in the fields of social sciences and community-based work. The prizes will be presented at the Prizes and Awards Ceremony on Friday 19 April.

BHIVA Science Scholarships
Science Scholarships have been awarded to 10 researchers and scientists whose abstracts have been accepted for presentation. All registration fees, a contribution towards travel expenses and accommodation costs are paid by BHIVA to successful candidates.

BHIVA Community Registrations and Scholarships
Community Scholarships have been awarded to 10 UK-based community registrants to assist them to attend the conference. For those applicants selected, all registration fees and a contribution towards expenses and accommodation costs are paid by BHIVA. In addition, BHIVA has supported free registration for almost 50 community representatives to attend the conference.

BHIVA Registration Scholarships
Registration Scholarships have been awarded to up to 20 delegates who are either healthcare professionals who are retired, not working, or employed in a part-time or equivalent capacity, or who are students involved in full-time undergraduate or postgraduate work. The scholarship covers the conference registration fee.

BHIVA/AbbVie/SSAT (BASS) Exchange Scholarships
AbbVie, in collaboration with the British HIV Association (BHIVA) and the St Stephen’s AIDS Trust (SSAT), have set up an exchange scholarship for practising HIV doctors, under 35 years of age and from developing and transition countries, to travel to the UK for training purposes. The objective is to increase their understanding of the treatment and management of HIV and to disseminate this information and experience when they return to their country of origin. Successful overseas candidates have been invited to participate in a training programme in the UK and to attend the 19th Annual Conference of the British HIV Association in Manchester, UK on 16–19 April 2013. In exchange, a scholar from the UK (SpR or StR grade) has travelled to the home country of a winning overseas applicant in order to take part in a placement at an HIV centre or hospital. Winning scholars will be acknowledged during the Prizes and Awards Ceremony on Friday 19 April.

MSD International Travel Bursaries in collaboration with BHIVA
MSD, in collaboration with the British HIV Association (BHIVA) have launched travel bursary schemes for the 20th CROI conference held in Atlanta, USA in March 2013, and the 14th EACS conference to be held in Brussels, Belgium in October 2013. Scholarships have been provided to assist UK-based consultants and non-consultant healthcare professionals (including doctors, nurses, pharmacists and non-clinical researchers). A minimum of five places will be awarded to newly-appointed consultants (within first 5 years of appointment) and non-consultant healthcare professionals (within 7 years of current appointment) in the field of HIV medicine. All applicants must be members of the British HIV Association (BHIVA). Winning applicants of travel bursaries to the 20th CROI conference will be acknowledged during the Prizes and Awards Ceremony on Friday 19 April.
Civic Welcome Reception

Exchange Hall
Manchester Central Convention Complex

Wednesday 17 April 2013 : 1900–2000

Manchester Central Convention Centre is an award-winning conference and exhibition venue in the heart of the city of Manchester. Formerly known as G Mex and the Manchester International Conference Centre, it was re-branded in 2007 to bring together the entire site under one brand.

Manchester Central has been recognised with numerous awards in various categories including architecture and design, branding and business tourism. The venue’s first awards came following its conversion from a disused railway station into an exhibition centre, one of the UK’s first urban regeneration projects.

The Civic Welcome Reception will be held in Exchange Hall (exhibition hall) and include addresses from the Conference Local Host, Dr Ed Wilkins, and the Chair of the British HIV Association, Professor Jane Anderson. We are also honoured that the Lord Mayor of the City of Manchester, Councillor Elaine Boyes, and the Patron of the British HIV Association, Lord Norman Fowler, have kindly agreed to speak as part of our Civic Welcome Reception.

The event will include an opportunity for delegates to network whilst enjoying a drink and some light refreshments. There will also be entertainment from a string quartet.

Gala Dinner

Dress code: Gentlemen are requested to wear jacket and tie

Ticket required

The Monastery
Gorton Lane, Manchester M12 5WF

Thursday 18 April 2013 : 2000–0030

Manchester’s magnificent Monastery is Pugin’s architectural masterpiece. The historic buildings were built between 1863 and 1872 by Franciscan monks who had come to Manchester in 1861 to serve the local Catholic community. Designed by Edward Pugin, whose father helped design the houses of Parliament, Gorton Monastery is considered one of his finest masterpieces and is Grade II listed.

The Monastery was for some 120 years the hub of religious, social and cultural activity but it was sadly vacated by the Franciscans in 1989 and, after a false start for a new use, was left prey to significant vandalism and theft. Following a 12-year fundraising campaign The monastery has been saved from ruin and the original site has been restored.

The Gala Dinner will commence with a drinks reception followed by dinner. After some short speeches, entertainment will include music from the International Party Doctors, one of the UK’s foremost function bands.
BHIVA PLENARY SPEAKERS: BIOGRAPHIES

Jonathan Ainsworth is Lead for HIV and Haematology and R&D director of the North Middlesex University Hospital. His research interests include haemophagocytic lymphohistiocytosis in patients with sepsis and HIV, and the role of Mycoplasma fermentans in disease.

Jane Anderson works at Homerton University Hospital NHS Foundation Trust in East London. Professor Anderson’s clinical practice and research interest focus on HIV in ethnic minority and migrant populations in the UK, with a special interest in the care of women with HIV. She is the currently elected Chair of the British HIV Association (2011–2014).

Alejandro Arenas-Pinto is Senior Clinical Research Associate at the UCL Centre for Sexual Health and HIV Research, and Senior Clinical Research Scientist at the MRC Clinical Trials Unit, where he works on a number of adult ART trials, including PIVOT, START, NEAT-001, EARNEST and their sub-studies.

José Arribas is the Research Director of HIV and Infectious Diseases at La Paz Hospital, and Associate Professor of Medicine at Autonoma University School of Medicine in Madrid. He is a member of the Spanish Group for the Study of AIDS and the European AIDS Clinical Society Governing Board.

David Asboe studied medicine at Otago University, New Zealand and completed specialist training in Genitourinary Medicine at St Thomas’ Hospital, London. He is a consultant in HIV Medicine and Sexual Health at Chelsea and Westminster Hospital. His special interests are antiretroviral resistance, and sexual health of people living with HIV. He is the Convenor of the Diploma HIV Medicine exam, run by the Worshipful Society of Apothecaries, and is a Trustee on the Executive Committee of the British HIV Association.

Nathaniel Ault is the Consultant HIV Nurse at Barts and The London Trust. He has worked in HIV for over 20 years in various posts across the community, acute, palliative and voluntary sectors. He has a first degree in psychology and a masters degree in nursing (Advanced Practitioner). He is currently Chair of the National HIV Nurses Association.

Marta Boffito trained in general medicine and infectious diseases at the Universities of Turin, and San Francisco. She gained her PhD in 2004 at the University of Liverpool, with a thesis on the pharmacokinetics and pharmacodynamics of antiretroviral therapy. She is a consultant physician (Chelsea and Westminster Hospital), Clinical Lead in Clinical Trials (St. Stephen’s AIDS Trust) and an honorary senior lecturer (Imperial College), where, in addition to her clinical duties, she is heavily involved in numerous research projects.

Charles Boucher is Professor in the Department of Virology, Erasmus Medical Center, Erasmus University, Rotterdam. He received his medical degree cum laude from the Faculty of Medicine of the University of Amsterdam. Specialising in medical microbiology, he also received a PhD degree from the same institution. Since then, he has been a research assistant at the University of Amsterdam and a visiting fellow at Wellcome Research Laboratories in Beckenham. He has also furthered his studies in clinical microbiology and virology at the Academic Medical Center, Amsterdam and the University Medical Center, Utrecht. He is the chairman of the European Society for Antiviral Resistance, and has over 240 publications in the field of virology. He is a member of the National Institutes of Health (United States), the PENTA Committee Advisory Board, the Antiviral Research Society and the International AIDS Society.

Mark Bower is professor of oncology at Imperial College with a specialist interest in HIV associated malignancy and is lead clinician for the National Centre for HIV malignancy at Chelsea & Westminster Hospital. He chairs the BHIVA malignancy guidelines group. He has a clinical and basic research programme studying aspects of HIV malignancy.

Elaine Boyes began her career as a secretary, including 13 years with the National Computing Centre, followed by a secondment to the Department of Trade and Industry. She worked for 18 years as a receptionist at a local GP’s practice. She has been a member of Manchester City Council since 2006, representing the City Centre ward. She has been actively involved with the local community over many years, and has been a member of the Health and Wellbeing Scrutiny Committee, the Planning Committee, and the Children and Young People’s Overview and Scrutiny Committee. She was also a Regulation 33 Visitor for three years, a role which involves visiting children’s homes unannounced to ensure they are of a good enough quality for the young people living there. Her chosen theme for her year of office is disability issues, particularly adults with disabilities. She has a particular interest in Alzheimer’s, dementia and Multiple System Atrophy (MSA).
Jane Bruton is the Nurse Consultant for HIV at Chelsea and Westminster NHS Foundation Trust. She has worked in HIV since 1987 and has an MA in Medical Anthropology. She is on the NHVNA Executive Committee and co-authored the National HIV Nursing Association Competencies.

Katherine Clay is currently an infectious diseases registrar at Birmingham Heartlands Hospital with an interest in HIV medicine. During her training she spent a year working on the HIV ward at Chelsea and Westminster Hospital. She was selected to be the specialist registrar on the BHIVA Audit and Standards Subcommittee to work on the 2012/13 project, which is an audit of non-retention in care.

Calvin Cohen is the Research Director of Community Research Initiative of New England, and Clinical Research Director for Harvard Vanguard Medical Associates where he has an Internal Medicine practice focused on HIV. He is a Clinical Instructor at Harvard Medical School. He gained his MD from the Albert Einstein College of Medicine, and his MSc from the Harvard School of Public Health. His research has focused on HIV antiviral trials since 1985. He is currently a Vice Chair of the Scientific Steering Committee of the INSIGHT network, an NIH-supported international network of clinician-researchers. He has received the Outstanding Physician Award by Harvard Vanguard Medical Associates, and the Ebert Teaching award by Harvard Pilgrim Health Care.

Simon Edwards has been a Consultant in GU/HIV Medicine at the Mortimer Market Centre and UCLH since 2000. He is the current Chair of the BASHH HIV Special Interest Group. He was Co-Chair of the BHIVA Guidelines for Opportunistic Infections (2011) and is currently a section lead for the writing group for the upcoming HIV treatment guidelines. He is an examiner for the Diploma in HIV Medicine. He has previously been on the BHIVA Executive Committee (2005/8).

Carol Emerson has been a consultant in HIV/GUM at the Royal Victoria Hospital, Belfast Trust since August 2008. She has been the BHIVA junior consultant and non-consultant representative since September 2010 and, as part of the role, established the Young Consultants’ Forum at the BHIVA spring meeting. She sits on the BHIVA Conferences and Education and Scientific Subcommittees.

Norman Fowler served for 10 years in Margaret Thatcher’s cabinet. He was Health Secretary for six of those years – the longest serving Health Secretary since the war – combining it with responsibility for Social Security. Later, he was chairman of the Conservative Party under John Major and Shadow Home Secretary under William Hague. In the House of Lords he was first chairman of the Communications Select Committee and most recently has chaired a select committee on HIV and AIDS – 25 years after his ‘Don’t Die of Ignorance’ campaign. The committee’s report No vaccine; No cure was published in September 2011. He is currently writing a book about the HIV position around the world.

Caroline Fryar is a medico-legal adviser. She studied medicine at the University of Sheffield and went on to train as a GP in Cheshire, gaining MRCGP in 2005. Caroline joined the MDU in 2006. She completed her LLM in Legal Aspects of Medical Practice in 2011 and became a Member of the Faculty of Forensic and Legal Medicine in 2012.

Romas Geleziunas is a Director in the Clinical Virology Department at Gilead Sciences, Inc. He received his PhD in Microbiology and Immunology from McGill University, Montreal, and conducted post-doctoral studies at the University of California, San Francisco. He has worked on HIV for 26 years in both academia and the pharmaceutical industry. At Gilead, he has led multidisciplinary HIV antiviral drug discovery and early drug development programs, has established and led Gilead’s HIV eradication program, and is currently the head of the HIV Advanced Therapies group. He is also a member of the NIAID ACTG HIV Reservoirs and Viral Eradication Transformative Sciences Group.

Margaret Johnson is the Clinical Director of the Royal Free Centre for HIV Medicine and is Professor of HIV Medicine at University College London. She has been involved in the management of women with HIV infection since 1989, when she was appointed the first HIV physician in the UK. One of her first projects on appointment was the development of a designated HIV clinic for women. More recently she chaired the British HIV Association from 2004 to 2008. Together with Professor Jane Anderson, she has chaired BHIVA guidelines for the management of women with HIV.
Clifford Leen is a consultant physician in Infectious Diseases and HIV at the Western General Hospital Edinburgh. He now leads a research unit involved in international and national studies on the treatment of HIV and hepatitis C and was the Secretary of the BHIVA Hepatitis Working Group Executive Panel. He is a member of the BHIVA and Scottish HIV Advisory Group (SHIVAG) executive committees, and has been on the BHIVA Treatment Guidelines Writing Committee since 2003. He is Training Programme Director for Infectious Diseases in Scotland. He chaired the BHIVA Education and Scientific Subcommittee from 2008 to 2011, and has been a member of the management group of Edinburgh University’s Centre for Infectious Diseases since 2008.

Andrew Lever graduated in Biochemistry and Medicine from the University of Wales. Following clinical training, he performed research in immunodeficiency and infectious diseases in London and Harvard, where his work focused on HIV infection. He was appointed senior lecturer at St George’s Hospital, London in 1989 and moved to Cambridge in 1991. He was appointed to a Personal Chair in 2000. He is an Honorary Consultant in Medicine and Infectious Diseases and is Head of Academic Infectious Diseases at the University of Cambridge. He is clinically active in ID and chairs the Hospital Infection Control Committee. He runs a research group working on HIV and rotaviruses. He was a member of the UK Department of Health Gene Therapy Advisory committee from 1999–2006. He was awarded the Lennox Black International prize in Medicine from Thomas Jefferson University, Philadelphia in 2002; elected Fellow of the Academy of Medical Sciences in 2000; and Fellow of the Royal Society of Chemistry in 2006.

Marc Lipman is an HEFCE-NHS Clinical Senior Lecturer and Consultant in Respiratory and HIV Medicine at the Royal Free London NHS Foundation Trust & University College London. His research interests focus on tuberculosis, respiratory infection and HIV – with a particular interest in translational and health services research.

Sebastian Lucas is a committed infectious disease specialist pathologist, starting work on HIV clinical pathology in the mid-1980s whilst at UCH & Middlesex Hospitals. That led to much HIV autopsy work in London and West Africa, which buttressed his appointment to the Chair of Pathology at Guy’s & St Thomas’ Medical School (now part of KCL) in 1995. Although he formally retired in 2012, he continues the HIV interest, underlining the importance of good pathology diagnostics, appropriately investigated deaths, education, and clinico-pathological correlation to improve patient care.

David Mabey is a physician specialising in infectious diseases. He became interested in STIs and in ocular Chlamydia trachomatis infection (trachoma) while working as a clinician at the MRC Laboratories in The Gambia in the 1980s, and has been involved in research projects on STIs in Tanzania, Uganda, Zambia, China, Brazil and Peru.

Mark Nelson is a consultant physician at the Chelsea and Westminster Hospital, London and adjunct reader at Imperial College London. He sits on the Executive Committee of the British HIV Association, and is Chair of the Education and Scientific Subcommittee. He is a trustee of St Stephen’s AIDS Trust, and was head of overseas education for this charity until focusing his efforts on working with the Green Shoots Foundation, developing educational programmes in Vietnam and Myanmar. He has been awarded a visiting professorship at the Aga Khan Hospital, Nairobi, Kenya and the certificate of merit by the government of Vietnam.

Colm O’Mahony is a consultant at Chester. He read Science and Medicine at University College Dublin and later an MD in immunology. He trained in STD/HIV in Liverpool, working in the famous Q Clinic and Seamen’s Dispensary. He was Chairman of the Association for Genito-Urinary Medicine, and has served on the BHIVA Executive Committee. In the BASHH media group he has had dealings with the media, emphasising access problems, under-funding and HPV vaccination. He runs media training and presentation skills courses for the European Association of Dermatovenereology.

Anton Pozniak studied medicine at the University of Bristol and qualified in 1979. He started caring for patients with HIV in 1983 at the Middlesex Hospital. He worked as a consultant physician in Zimbabwe where he researched for his doctorate in TB/HIV, before moving back to the UK in 1991. He ran the HIV Research Unit at King’s College, London before moving to his current position as consultant physician/senior lecturer at the Chelsea and Westminster Hospital in 1998. He became a fellow of the Royal College of Physicians in 1996. He is Director of HIV Services and Lead TB Physician. He has been made a Life Member of the British HIV Association and sits on the Guidelines Subcommittee. He sits on the Expert advisory group on AIDS for the UK Department of Health. He is an Executive Member the European AIDS Clinical Society and is Treasurer of the IAS. He is Chair of the European AIDS trial network Foundation NEAT-ID, and a member of the WHO HIV Guidelines Committee for 2013. He is on the Scientific Advisory Board and Executive Committee of the St Stephen’s AIDS Trust.
Caroline Sabin is Professor of Medical Statistics and Epidemiology at UCL. She has worked for many years on the analysis of large observational HIV databases, with a particular interest in raising awareness of the biases inherent in these databases. She is the Principal Investigator of the UK CHIC Study, is the Principal Statistician on the D:A:D Study, and works with many other research groups in the UK and elsewhere. She is a member of the Scientific Leadership group for the EU-funded EuroCoord Network of Excellence.

Margaret Stanley is Emeritus Professor of Epithelial Biology in the University of Cambridge and Fellow of Christ’s College. She attended the Universities of London, Bristol and Adelaide, and is a Fellow of the Academy of Medical Sciences and Honorary Fellow of the UK Royal College of Obstetricians and Gynaecologists. She was a member of the Biology and Biotechnology Science Research Council from 2000–2003, a member of the Spongiform Encephalopathies Advisory Committee that advised the UK government on prion diseases, and in 2004 was awarded the OBE for services to Virology. In 2010 the American Society for Colposcopy and Cytology recognised her with a Lifetime Achievement Award. Her current research focuses on mechanisms of host defence and the development of vaccines and immunotherapies against human papillomaviruses, the cause of cervix cancer.

Andrew Ustianowski is a consultant physician in Infectious Diseases & Tropical Medicine, and clinical director, at the Monsall Regional Infection Unit, North Manchester General Hospital, which has a cohort of around 2000 HIV-positive patients. He has been part of guideline writing committees for BHIVA and other bodies, lectures widely on HIV, hepatitis and related topics, and is part of several educational steering groups.

Ed Wilkins is a consultant in Infectious Diseases and Director of the HIV Research Unit at North Manchester General Hospital. Prior to taking up his current position, he trained in Infectious Diseases in London and Liverpool, Tropical Medicine in Africa, and Medical Microbiology with the Health Protection Agency. He has been involved with HIV patient care and research since 1984, with interests in antiretroviral toxicity and hepatitis co-infection. He is heavily involved in clinical trials as well as many executive and advisory national committees including BHIVA.

Alan Winston is a consultant physician in HIV and GU Medicine at St Mary’s Hospital, London and a senior lecturer at Imperial College London. His research interests include antiretroviral pharmacokinetics, focusing on sanctuary sites, and co-morbidities in HIV-disease, focusing on cerebral disease. He runs the HIV Clinical Trials Unit at St. Mary’s Hospital and is a member of the European AIDS Clinical Society Co-morbidity Guidelines Panel and the British HIV Association Treatment Guidelines Panel.
SPONSORS AND EXHIBITORS

BHIVA MAJOR SPONSORS

AbbVie Laboratories Limited
AbbVie House,
Vanwall Business Park
Maidenhead
Berkshire SL6 4XE

Boehringer Ingelheim Limited
Ellesfield Avenue
Bracknell
Berkshire RG12 8YS

Bristol-Myers Squibb Pharmaceuticals Limited
Uxbridge Business Park
Sanderson Road
Middlesex UB8 1DH

Gilead Sciences Limited
Granta Park
Great Abington
Cambridgeshire CB21 6GT

MSD Limited
Hertford Road
Hoddesdon
Hertfordshire EN11 9BU

Janssen
50–100 Holmers Farm Way
High Wycombe
Buckinghamshire HP12 4EG

ViiV Healthcare UK Limited
Stockley Park West
Uxbridge
Middlesex UB11 1BT

CONFERECE EXHIBITORS

Pharmaceutical and Commercial

6PM Healthcare
Alcura
Blithe Computer Systems
BMS Virology Partnership
Galen
Healthcare at Home
QIAGEN

Affiliated, Educational and Charitable

Children’s HIV Association
Dietitians Working in HIV/AIDS
HIV Pharmacy Association
Justri (The Training and Resource Initiative)
Marie Stopes International
National HIV Nurses Association (NHIVNA)
Saving Lives

Community

BASELINE
Centre for All Families Positive Health
Ffena Network of African HIV Policy Network

George House Trust
HIV i-Base
NAM
National AIDS Trust
Positively UK
Terrence Higgins Trust
The Sophia Forum

UK Community Advisory Board

The 19th Annual Conference is organised and administered by Mediscript Ltd

Medical Education Publishing · Conferences · Secretariat
FORTHCOMING EVENTS

Manchester · 2013

7th Annual Conference of the National HIV Nursing Association (NHVNA)

27–28 June 2013

The International Convention Centre, Birmingham

Joint BHIVA/BASHH One-day Revision Course for the Diploma in HIV Medicine

Monday 2 September 2013

St Thomas’ Hospital, London

Controlling the HIV Epidemic with Antiretrovirals: from Consensus to Implementation

in partnership with British HIV Association (BHIVA)

22–24 September

Queen Elizabeth II Conference Centre, London

17th Annual Resistance and Antiviral Therapy Meeting

Wednesday 3 October 2013 (tbc)

London

6th Annual BHIVA Conference for the Management of HIV/Hepatitis Co-infection

in collaboration with British Association for the Study of the Liver (BASL) and British Viral Hepatitis Group (BVHG)

Wednesday 13 November 2013

Queen Elizabeth II Conference Centre, London

BHIVA Autumn Conference

including CHIVA Parallel Sessions

14–15 November 2013

Queen Elizabeth II Conference Centre, London

For further information on these events, please contact:

Mediscript Ltd
1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD
Tel: 020 8369 5380 Fax: 020 8446 9194
Email: bhiva@bhiva.org Web: www.bhiva.org

Prescribing information (UK) Tablets & Suspension

VIRAMUNE: prolonged-release tablets

Prolonged-release tablets containing 50 mg, 100 mg or 400 mg nevirapine. Action: Non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Indication: For use in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults, adolescents and children of any age. Dose & administration: Adults: 200 mg once daily (PO) for 14 days, then 100 mg twice daily. Tablets containing 200 mg nevirapine may be halved or crushed and administered with: Food, fluids, milk, nonalcoholic carbonated drinks. Tablets & suspension should be taken with or without food. Tablets & suspension should not be taken during diarrhoea. Tablets & suspension should not be taken after vomiting. For further information on dose & administration, see SPC. Pack sizes and NHS price: 90 x 50 mg tablets £86.00; 30 x 100 mg tablets £112.50; 10 x 200 mg tablets £170.00. Prescribing information (UK) Tablets

Tablets containing 200 mg nevirapine oral suspension containing 10 mg/ml nevirapine. Action: Non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Indication: For use in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults, adolescents and children of any age. Dose & administration: Adults: 200 mg once daily (PO). Tablets containing 200 mg nevirapine may be halved or crushed and administered with: Food, fluids, milk, nonalcoholic carbonated drinks. Tablets should be taken with or without food. Tablets should not be taken during diarrhoea. Tablets should not be taken after vomiting. For further information on dose & administration, see SPC. Pack sizes and NHS price: 150 x 100 mg tablets £112.50. Prescribing information (UK) Prolonged-release tablets

Prolonged-release tablets containing 150 mg once daily or 200 mg once daily. Action: Non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Indication: For use in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults, adolescents and children of any age. Dose & administration: Adults: 200 mg once daily (PO) for 14 days, then 100 mg twice daily. Tablets containing 200 mg nevirapine may be halved or crushed and administered with: Food, fluids, milk, nonalcoholic carbonated drinks. Tablets & suspension should be taken with or without food. Tablets & suspension should not be taken during diarrhoea. Tablets & suspension should not be taken after vomiting. For further information on dose & administration, see SPC. Pack sizes and NHS price: 90 x 50 mg tablets £86.00; 30 x 100 mg tablets £112.50; 10 x 200 mg tablets £170.00. Prescribing information (UK) Suspension

Oral suspension containing 10 mg/ml nevirapine. Action: Non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Indication: For use in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults, adolescents and children of any age. Dose & administration: Adults: 200 mg once daily (PO). Tablets containing 200 mg nevirapine may be halved or crushed and administered with: Food, fluids, milk, nonalcoholic carbonated drinks. Tablets & suspension should be taken with or without food. Tablets & suspension should not be taken during diarrhoea. Tablets & suspension should not be taken after vomiting. For further information on dose & administration, see SPC. Pack sizes and NHS price: 150 x 100 mg tablets £112.50. References

Alongside excellent control rates, Viramune has demonstrated a favourable neuropsychiatric profile and beneficial effects on lipid metabolism; making it a key ART treatment for the last fifteen years.1-10

With the introduction of VIRAMUNE prolonged-release, you get all the benefits of Viramune in a once-daily pill.7

So, when you think Viramune, write VIRAMUNE prolonged-release.

*If they’re treatment naïve and have a CD4 count <400/mm³ (him) or <250/mm³ (her) or they’re switching treatment and have an undetectable viral load

Prescribing information and references can be found overleaf

UK/NVP-131006  Date of preparation: February 2013
Based on ECHO and THRIVE 48-week data, EDURANT is now licensed for patients new to antiretroviral (ARV) therapy with a viral load ≤100,000 copies/mL.

It’s about the fit.

INDICATION: In combination with other antiretroviral medicinal products (ARVs), EDURANT is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤100,000 HIV-1 RNA copies/mL. Please see Summary of Product Characteristics.

INTERACTIONS: Use with caution when co-administering EDURANT with other medicinal products that induce or inhibit CYP3A and those that increase gastric pH. EDURANT may inhibit intestinal P-glycoprotein and affect medicinal products transported by P-glycoprotein e.g. digoxin and may alter the effects of medicinal products transported by P-glycoprotein e.g. dabigatran so use with caution. Careful patient monitoring advised when starting or ending concomitant treatment with metformin. Rilpivirine inhibits the secretion of creatinine. Where possible, alternatives such as azithromycin should be considered in place of clarithromycin, erythromycin and troleandomycin. Only H2-receptor antagonists that can be dosed once daily, using a strict dosing schedule, should be used. Antacids should be used with caution and only, either at least 2 hours before or 4 hours after EDURANT. Clinical monitoring recommended with methadone, as maintenance therapy may need to be adjusted. When using diphenoxylate levels should be monitored.

LEGAL CATEGORY: POM

FURTHER INFORMATION AVAILABLE FROM: Janssen-Cilag Ltd, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK © 2012 Janssen-Cilag Ltd

Prescribing Information last revised: 10/2012

PHGB/EDU/0113/0020
Date of preparation: January 2013

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Janssen-Cilag Ltd on 01494 567447.